These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18387065)

  • 21. Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.
    Liu JW; Chen YH; Lee WS; Lin JC; Huang CT; Lin HH; Liu YC; Chuang YC; Tang HJ; Chen YS; Ko WC; Lu MC; Wang FD
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
    Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
    Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
    Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
    Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections.
    Greenberg RN; Cayavec P; Danko LS; Bowen K; Montazemi R; Kearney PA; Johnson SB; Strodel WE
    J Antimicrob Chemother; 1994 Sep; 34(3):391-401. PubMed ID: 7829413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
    Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
    Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical experience with chemotherapy using sulbactam/cefoperazone for severe infections accompanying malignant hematological disorders].
    Fujii Y; Ayame H; Inoue H; Fujita N; Miyoshi K; Murano K; Hatao K; Yaga K; Kaku K; Kaneko T
    Jpn J Antibiot; 1990 Jun; 43(6):1143-51. PubMed ID: 2232145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection].
    Iakovlev VP; Krutikov MG; Alekseev AA; Grishina IA; Izotova GN; Kashin IuD
    Antibiot Khimioter; 1995 May; 40(5):38-41. PubMed ID: 8534180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study on sulbactam/cefoperazone in urinary tract infections in elderly patients].
    Oyabu Y
    Jpn J Antibiot; 1996 Mar; 49(3):250-5. PubMed ID: 8935120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of cefoperazone and cefoperazone plus sulbactam in a neutropenic site model.
    Fasching CE; Moody JA; Sinn LM; Tenquist J; Gerding DN; Peterson LR
    Diagn Microbiol Infect Dis; 1991; 14(2):147-55. PubMed ID: 1873973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment.
    Dong Y; Li Y; Zhang Y; Zhang T; Zhu L; Dong Y; Wang T
    Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):353-359. PubMed ID: 31056857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of sulbactam/cefoperazone for infections during the chemotherapy of hematologic malignancy].
    Kawai Y; Ueda T; Iwasaki H; Nakamura T
    Jpn J Antibiot; 1994 Sep; 47(9):1196-201. PubMed ID: 7990260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical evaluation of combination therapy with sulbactam/cefoperazone and amikacin sulfate for infections associated with hematological disorders].
    Fukuda M; Hirashima K
    Jpn J Antibiot; 1993 Oct; 46(10):912-7. PubMed ID: 8254893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.
    Lan SH; Chang SP; Lai CC; Lu LC; Tang HJ
    Medicine (Baltimore); 2020 Feb; 99(8):e19321. PubMed ID: 32080150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.
    Clay PG; Graham MR; Lindsey CC; Lamp KC; Freeman C; Glaros A
    Am J Geriatr Pharmacother; 2004 Sep; 2(3):181-9. PubMed ID: 15561650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.
    Bodey GP; Elting LS; Narro J; Koller C; O'Brien S; Estey E; Benjamin R
    J Antimicrob Chemother; 1993 Jul; 32(1):141-52. PubMed ID: 8226405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis.
    Lan SH; Chao CM; Chang SP; Lu LC; Lai CC
    Surg Infect (Larchmt); 2021 Oct; 22(8):763-770. PubMed ID: 33625294
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.